Brellium’s $23 Million Bet Beyond ABA — Without Leaving It Behind

As Brellium expands beyond behavioral health, deeper ABA integrations and its CortexLM architecture offer a glimpse of how specialized technology can scale across healthcare.

Brellium announced an additional $23 million in funding this week, led by Left Lane Capital with participation from First Round Capital. The company also introduced CortexLM, its proprietary harness for identifying documentation, compliance, and care quality gaps across patient visits.

The investment will support expansion beyond Brellium’s roots in behavioral health, including ABA, and hospice into primary care and medical specialties such as cardiology.

For ABA providers, that raises an obvious question: As Brellium pursues a much larger healthcare market, what happens to its investment in ABA?

I spoke with Brellium co-founder and CEO Zach Rosen following the announcement. As he put it:

“ABA absolutely remains a core market for Brellium. This investment is about expanding our product capabilities and expanding into additional healthcare markets. We’re continuing investing in our ABA capabilities and building deeper integrations with the platforms our customers use.”

That distinction matters because Brellium’s recent partnerships suggest its role within the ABA technology stack may be evolving even as the company expands beyond it.

Going Deeper Into the ABA Stack

Earlier this year, Brellium announced a partnership with RethinkFirst, bringing automated documentation quality and compliance review into the Rethink Behavioral Health Marketplace. Brellium has reported processing more than 40,000 audits weekly for Rethink customers.

More recently, Motivity announced an integration designed to bring automated documentation auditing and correction workflows closer to the clinical activities occurring within its platform.

These integrations are already bringing Brellium closer to the clinical workflows managed by practice management platforms. Rosen indicated that the company intends to go further, pursuing deeper technical integrations, although he wasn’t ready to share specifics.

The distinction between an integration that transfers data and one that embeds functionality into a clinical workflow is significant.

Brellium already sends audit feedback to clinicians and supervisors. The open question is whether correction and resolution happen inside the system where the note lives, or alongside it. When a finding, its fix, and the record of that fix all sit in the same workflow, auditing becomes an operational process rather than a parallel one.

For ABA organizations, the opportunity is to make quality assurance part of everyday clinical work rather than a separate retrospective activity.

For Brellium, deeper integrations could make its specialized technology more valuable without requiring the company to become a practice management system itself.

The Challenge of Being an Independent Layer

There’s an inherent tension in this approach.

Specialized platforms depend on access to clinical and operational data maintained by larger practice management systems. Those systems control integration pathways and increasingly have incentives to develop overlapping functionality.

Practice management vendors already control the workflows where documentation is created, giving them a natural starting point for developing their own quality controls. RethinkFirst, for example, offers AI-assisted note generation while partnering with Brellium for auditing. The two capabilities are complementary today, but they illustrate how the boundaries between native functionality and specialized technology could evolve.

That creates a familiar build-versus-partner decision.

A practice management vendor can develop native functionality, integrate with a specialized provider, or offer some combination of the two. For an independent company like Brellium, the challenge is to deliver enough differentiated value that customers continue to want it regardless of which underlying system they use.

Brellium’s growing integration relationships suggest one possible answer: specialize in the intelligence layer while allowing practice management platforms to remain the systems of record.

But the long-term success of that model will depend on both the quality of Brellium’s technology and its ability to remain connected to the workflows where providers need it.

CortexLM: Scaling the Underlying Intelligence

The other significant announcement was CortexLM.

While introduced publicly alongside the funding, Rosen described CortexLM as an AI harness that has already been operating within Brellium for several months. Rather than representing an entirely new product that customers must adopt, it underpins Brellium’s existing documentation review capabilities.

Its potential differentiation lies in how quickly Brellium can adapt that intelligence to different organizations and clinical settings.

Rosen described how Brellium’s experience reviewing millions of ABA patient visits informs its underlying technology. He said CortexLM also helps the company translate individual customer requirements into configured audits more quickly, reducing the effort required to bring new organizations onto the platform.

That’s a different proposition from simply applying a general-purpose AI model to clinical notes.

Documentation requirements vary by payor, specialty, organization, and sometimes individual workflows. Identifying a potential documentation deficiency is only part of the challenge. The system also needs to understand which requirements apply, evaluate the documentation against them, and produce findings that clinicians can act on.

If CortexLM can make that configuration process more repeatable, Brellium may be able to enter new healthcare markets without rebuilding its auditing capabilities for each specialty.

It could also benefit ABA customers as payor requirements and documentation expectations evolve.

Brellium reports having audited 22 million patient visits across more than 200 healthcare organizations and 215,000 providers. Those are companywide figures, not measures of ABA adoption, but they illustrate the scale the company is pursuing.

What This Means for ABA

Brellium framed the raise around a specific pressure: payors have sharply increased scrutiny of healthcare billing, and organizations acting in good faith are increasingly caught in it. For ABA providers, the stakes are concrete: payors are examining whether billed services are adequately supported by clinical records.

Brellium’s funding is another indication that investors see opportunity in healthcare technology addressing documentation quality, compliance, and revenue integrity.

Brellium is pursuing a broader healthcare market while continuing to invest in ABA. Its recent partnerships point toward deeper integration with the systems providers already use, while CortexLM offers a common technology foundation that can support multiple clinical specialties.

For ABA providers, the question is whether that broader scale translates into better tools, stronger integrations, and more effective quality controls within their existing operations.

For the broader technology ecosystem, Brellium illustrates a different growth model: a specialized platform expanding across healthcare rather than attempting to own every component of the ABA operating stack.

The test will be whether Brellium can deepen its value within ABA while pursuing those larger markets.